Apr 22, 2002
PR Newswire - USA
The Immune Response Corporation announced today that it received notification from the European Patent Office confirming that the appeal proceedings relating to its T cell receptor peptide technology are closed. According to the notification, AstraZeneca and T Cell Sciences have unconditionally withdrawn their opposition to the Company's European Patent No. 0463101 entitled Vaccination Against Diseases Resulting From Pathogenic Responses By Specific T-Cell Populations. The Company's patent counsel has advised the Company that as a result of these events, the appeal procedure will be terminated and the decision of February 5, 1999 (by the European Patent Office) to uphold the Company's patent with all its original claims is final.
"We have been steadfast in our determination to protect the broad based intellectual property position of our T cell receptor peptide based therapeutic vaccine technology," said Dennis J. Carlo, Ph.D., the Company's President and Chief Executive Officer. "This favorable judgement to close a major opposition against our core technology further strengthens our patent estate and places us in a much stronger position. We can now offer potential corporate partners significant protected rights using our T cell receptor peptide technology for the treatment of rheumatoid arthritis (RAVAX(TM)), psoriasis (ZORCELL(TM)) and multiple sclerosis (NeuroVax(TM))."
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection. [NOTE: Company information can also be located on the Internet Web site: http://www.imnr.com/ ]
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether clinical trials will be successfully conducted and whether T cell receptor peptide based therapeutic vaccines will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation's SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2001 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
RAVAX(TM), ZORCELL(TM) and NeuroVax(TM) are registered trademarks of The Immune Response Corporation.
Contact: Investors, Kathy Lane of The Immune Response Corporation, +1-760-771-2236
All Material Subject to Copyright